Previous Close | 12.30 |
Open | 12.30 |
Bid | 9.00 |
Ask | 13.20 |
Strike | 115.00 |
Expire Date | 2024-10-18 |
Day's Range | 12.30 - 12.30 |
Contract Range | N/A |
Volume | |
Open Interest | 3 |
ALISO VIEJO, Calif., June 14, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million princi
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.